Outcomes of patients with therapy‐related myeloid neoplasms after treatment with poly(ADP‐ribose) polymerase proteins inhibitors for solid tumours.

Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights. Keywords: PARP inhibitors; therapy related myeloid neoplasms; therapy-related acute myeloid leukaemia; therapy-related myelodysplastic syndrome EN PARP inhibitors therapy related myeloid neoplasms therapy-related acute myeloid leukaemia therapy-related myelodysplastic syndrome e25 e29 5 04/20/23 20230501 NES 230501 Therapy-related myeloid neoplasms represent 10%-20% of all newly diagnosed myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML).[1] These disorders are frequently associated with high-risk genetic features. Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours Therapy related myeloid neoplasms, PARP inhibitors, therapy-related myelodysplastic syndrome, therapy-related acute myeloid leukaemia. [Extracted from the article]